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Cerebral near infrared spectroscopy oximetry in
extremely preterm infants: phase II randomised clinical
trial
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Abstract
Objective To determine if it is possible to stabilise the cerebral
oxygenation of extremely preterm infants monitored by cerebral near
infrared spectroscopy (NIRS) oximetry.
Design Phase II randomised, single blinded, parallel clinical trial.
Setting Eight tertiary neonatal intensive care units in eight European
countries.
Participants 166 extremely preterm infants born before 28 weeks of
gestation: 86 were randomised to cerebral NIRS monitoring and 80 to
blinded NIRS monitoring. The only exclusion criterion was a decision
not to provide life support.
Interventions Monitoring of cerebral oxygenation using NIRS in
combination with a dedicated treatment guideline during the first 72
hours of life (experimental) compared with blinded NIRS oxygenation
monitoring with standard care (control).
Main outcome measures The primary outcome measure was the time
spent outside the target range of 55-85% for cerebral oxygenation
multiplied by the mean absolute deviation, expressed in %hours (burden
of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives
5%hours of hypoxia. Secondary outcomes were all cause mortality at
term equivalent age and a brain injury score assessed by cerebral
ultrasonography.
Randomisation Allocation sequence 1:1 with block sizes 4 and 6 in
random order concealed for the investigators. The allocation was
stratified for gestational age (<26 weeks or ≥26 weeks).
BlindingCerebral oxygenationmeasurements were blinded in the control
group. All outcome assessors were blinded to group allocation.
Correspondence to: S Hyttel-Sorensen simonhyttelsrensen@gmail.com
Extra material supplied by the author (see http://www.bmj.com/content/350/bmj.g7635?tab=related#datasupp)
Recommendation for clinical interventions
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Results The 86 infants randomised to the NIRS group had a median
burden of hypoxia and hyperoxia of 36.1%hours (interquartile range
9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control
group, a reduction of 58% (95% confidence interval 35% to 73%,
P<0.001). In the experimental group the median burden of hypoxia was
16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6
(17.4-171.3) %hours in the control group (P=0.0012). Themedian burden
of hyperoxia was similar between the groups: 1.2 (interquartile range
0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4)
%hours in the control group (P=0.98). We found no statistically significant
differences between the two groups at term corrected age. No severe
adverse reactions were associated with the device.
ConclusionsCerebral oxygenation was stabilised in extremely preterm
infants using a dedicated treatment guideline in combination with cerebral
NIRS monitoring.
Trial registration ClinicalTrial.gov NCT01590316.
Introduction
About 25 000 infants are born extremely preterm every year in
Europe. Mortality of such infants is up to 20%, and about 25%
of survivors will have cerebral palsy or cognitive impairment.1-3
The first hours and days of a preterm infant’s life carry the
greatest risks of cerebral hypoxia and hyperoxia, because the
transition of the respiratory and circulatory systems just after
birth is associatedwith haemodynamic instability.4Low systemic
blood flow and fluctuations in systemic blood flow during these
first days of life are associated with poor neurodevelopmental
outcomes.5 6 To reduce the risk of impaired neurodevelopment,
effective preventive measures are needed.
Near infrared spectroscopy (NIRS) oximetry enables
non-invasive estimation of regional tissue haemoglobin oxygen
saturation (rStO2) because the ratio of the concentrations of
oxygenated haemoglobin to total haemoglobin in the penetrated
tissue are in the range of 0% to 100%.7 The NIRS sensor is
placed over the organ of interest; the rStO2 reflects primarily
the venous saturation of the blood in a volume of tissue to a
depth of about 2 cm.8 NIRS offers a direct, continuous measure
of the oxygen balance of the organ. rStO2 of the brain has been
shown to correlate with cerebral blood flow in adults and in
infants born at term.9 10 The thin skull of preterm infants makes
cerebral NIRS measurements well suited for this population.
Data on the association of cerebral rStO2 and long term outcomes
are limited in preterm infants. One study found low cerebral
rStO2 associated with lower developmental score at 2 years of
age in infants born very preterm.11 Two other studies found that
a low cerebral rStO2 on the first day of life was associated with
higher grade germinal matrix-intraventricular haemorrhage.12 13
In a piglet model it was shown that a low cerebral rStO2 must
be maintained some time before manifest brain damage
occurs.14 15 Furthermore, preclinical data suggest that hyperoxia
damages the immature brain.16 17 These results indicate that both
hypoxia and hyperoxia of the brain should be avoided, if
possible.
The Safeguarding the Brains of our smallest Children (www.
safeboosc.eu) project aims at testing the benefits and harms of
cerebral NIRS in the first days of life in extremely preterm
infants. Cerebral rStO2 monitoring and a dedicated treatment
guideline18 are the cornerstones of a brain oriented protection
strategy, with the goal of reducing periods of deleterious
imbalance between oxygen delivery and consumption. The pilot
showed that clinical implementation of this combined
intervention in a single centre was feasible.19 We designed a
phase II trial to test the hypothesis that the burden of hypoxia
and hyperoxia could be reduced by the combination of cerebral
NIRS monitoring and a dedicated treatment guideline, and to
demonstrate the feasibility of conducting a multicentre
randomised clinical trial with a complex intervention in infants
across Europe.20 The ultimate goal would be to increase the
survival of preterm infants without severe neurodevelopmental
impairment.
Methods
This is a phase II randomised, blinded, feasibility trial of a
medical device. The protocol is published elsewhere20 and is
available in full at www.safeboosc.eu. It was approved by each
hospital’s local research ethics committee, and, where required
(Austria, Denmark, France, and Switzerland) by the competent
authority responsible for medical devices. An independent data
and safety monitoring committee reviewed the interim safety
results. The study was monitored locally according to the
International Conference on Harmonisation guideline for good
clinical practice.21
Participants
Participants were recruited from the departments of neonatology
by the attending neonatologists or the local research staff in
Hopital Femme Mere Enfants, Lyon, France; Rigshospitalet,
Copenhagen, Denmark; La Paz University Hospital, Madrid,
Spain; Cork University Maternity Hospital, Cork, Ireland;
Wilhelmina Children’s Hospital, Utrecht, The Netherlands;
Medical University of Graz, Graz, Austria; Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; and
Rosie Hospital, Cambridge University Hospitals, United
Kingdom.
Inclusion criteria were infants born more than 12 weeks before
term (gestational age <27 weeks and six days) with a decision
to provide full life support and the possibility to start cerebral
NIRS monitoring within three hours after birth. Written
informed consent from the parents was mandatory before
inclusion and randomisation.
Cerebral NIRS monitoring
Based on data recordedwith the cerebral oximeter INVOS 5100c
using the adult SomaSensor (SAFB-SM) (Covidien, Boulder,
CO) on more than 400 preterm infants at the Wilhelmina
Children’s Hospital in Utrecht, the normal range of rStO2 in
stable very preterm infants has been defined to be from 55% to
85% during the first 72 hours of life (Petra Lemmers and Frank
van Bel, Utrecht, unpublished data). This range is considered
safe and the boundary thresholds for possible interventions as
listed in our treatment guidelines.18
SomeNIRS devices and sensors have systematic differences.22-24
We tested the suitability of devices by comparing absolute
values, repeatability, and sensitivity to changes in oxygenation
on the adult forearm.25 26 The predefined criteria were absolute
values and a dynamic range within 5% points of the INVOS
oximeter and absolute repeatability better than 6% (within
participant standard deviation) for acceptability of devices.
Eligible devices were the INVOS 5100Cwith adult SomaSensor,
NIRO 300, and NIRO 200NX with small probe holder
(Hamamatsu Phototonics, Hamamatsu City, Japan), and the
NONIN EQUANOX 7600 with adult sensor, model 8004CA
(Nonin Medical, Plymouth, MN).
Interventions
We randomised the infants to either the experimental group
with cerebral NIRS monitoring with visible reading of rStO2 or
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the control group with cerebral NIRS monitoring with blinded
rStO2. Monitoring was started within three hours of birth and
ended at 72 hours of life. In both groups the rStO2was recorded
every five or six seconds, depending on the device. In the
experimental group an rStO2 alarm warned when a burden of
0.2%hours (12%min) had accumulated during the past 10
minutes.19 A dedicated treatment guideline (see supplementary
file) was available for the clinical staff, listing possible
interventions to normalise an out of range rStO2. The
interventions were focused on respiratory and circulatory
support. It was emphasised that all other variables, such as blood
pressure, arterial saturation, and partial pressure of carbon
dioxide, should be kept within the target ranges in use in each
unit. The treatment guideline is described in detail elsewhere.18
Randomisation and masking
The web based randomisation was set up and handled by the
Copenhagen Trial Unit according to a computer generated
allocation sequence of 1:1 with block sizes 4 and 6 in random
order concealed for the investigators. The allocation was
stratified for gestational age (<26 weeks or ≥26 weeks).
Singleton infants were randomised individually and twins were
allocated to the same treatment group. If both twins could not
be included owing to lack of equipment, we included the infant
born last. Owing to a lack of NIRS devices in each unit, higher
order of multiple births could not be randomised.
The NIRS devices were either locked in a box, or we used a
device specific research mode rStO2 blinding. All data were
sent real time to a laptop. Software developed specifically for
the study could either show or conceal the current rStO2
depending on group allocation. Attending clinical staff manually
entered the details of repositioning of the sensor, as well as
physiological variables, such as blood pressure, mean airway
pressure, and blood gas variables (pH, partial pressure of carbon
dioxide, and partial pressure of oxygen. In addition, the
treatment interventions during the intervention period such as
treatment of a patent ductus arteriosus and number of blood
transfusions were recorded in the case record forms in both
groups.
Outcomes, adherence, and adverse events
The prespecified primary outcome was the time spent outside
the target range of 55-85% multiplied by the mean absolute
deviation during the first 72 hours after birth (burden of hypoxia
and hyperoxia), expressed in percentage hours (%hours) (fig
1⇓). One hour with an oxygenation of 50% gives 5%hours of
hypoxia. This figure could range from 0 to 3960%hours
(55%×72 hours) per participant. The burden was computed
blinded to allocation group from the raw rStO2 data and
extrapolated to 72 hours. There was no manual removal of
artefacts in the rStO2 data as there are no reliable ways for these
to be identified.
The secondary outcomes were all cause mortality at term
equivalent age and a brain injury score determined by
ultrasonography, as assigned by central, blinded reading of still
images of 13 prespecified slices (coronal and sagittal) at ages
1, 4, 7, 14, and 35 days and at term equivalent age. This brain
injury score is based on the occurrence and severity of
intracranial haemorrhages, white matter abnormalities,
ventricular dilation, and cerebral atrophy and is described in
detail in the protocol (www.safeboosc.eu). The secondary
outcome amplitude integrated electroencephalography has not
yet been analysed and will be reported separately. Exploratory
outcomeswere serious and non-serious adverse reactions, burden
of hypoxia, burden of hyperoxia, bronchopulmonary dysplasia
(defined as the need for supplementary oxygen at 36 weeks of
gestation), necrotising enterocolitis modified Bell’s stage 2 or
3,27 and retinopathy of prematurity stage 3 or worse.28
Statistical analyses
Sample size estimation
The sample size estimation was based on unpublished data on
23 extremely preterm infants with a mean burden of 76.0 (SD
83.2) %hours. We log transformed the data to achieve a normal
distribution with a mean of 1.64 (SD 0.50). The sample size
estimation was based on the assumptions to detect a 50%
reduction or more in burden of hypoxia and hyperoxia (mean
difference of 0.3 after log transformation), a type I error (α) of
5%, a power of 95%, a twin proportion of 30%, and an intraclass
correlation coefficient of 0.33.29 This required a total sample
size of 166 infants, approximately 83 per intervention group.
Analyses
All analyses were based on the intention to treat principle and
conducted blinded, with two sided tests at the 0.05 level of
significance. A mixed model for continuous outcome variables
with random intercepts corresponding to “birth clusters” and
ordinary logistic regression for binary (and ordinal) outcome
variables was planned per protocol. We adjusted the analyses
for the protocol specified variables (gestational age category
and trial centre). The former model was not significantly
different from amodel without random intercept (P=1.00) when
used for the adjusted analysis of the primary outcome. The
intraclass correlation of “birth clusters” was 0.027. All variables
showed only minor differences between the models. Therefore
we used the reduced model without “birth clusters” in all further
analyses. Multiple imputation was not necessary because of few
missing values. We adjusted the P values for the secondary
outcomes with Hommel’s procedure for multiplicity.
Calculations with different hypothetical P values for the planned
third secondary outcome (amplitude integrated
electroencephalography) were done, aiming for the most
conservative adjustment—that is, the highest adjusted P values.
Results
Between 1 June 2012 and 31 December 2013 we screened 370
infants for eligibility, and 166 were randomised (fig 2⇓). In four
instances only one twin could be included. Two infants in the
control group did not have any NIRS data recorded; one had
consent withdrawn and there were technical problems for the
other. All other data were collected per protocol for both. In the
remaining children the median monitoring time with an rStO2
signal was 67.7 hours (range 0.9-71.4 hours) with 67.9 hours
(interquartile range 64.7-69.0 hours) in the experimental group
and 67.4 (interquartile range 63.9-68.9) hours in the control
group. The variability in monitoring time was mainly due to
death within the first three days of life (two infants were
withdrawn from the trial by parental request and in four there
were technical reasons for reduced NIRS recording time).
The baseline characteristics of the two groups were similar (table
1⇓). The 86 infants randomised to the experimental group had
a median burden of hypoxia and hyperoxia of 36.1 %hours
(interquartile range 9.2-79.5%hours) compared with 81.3
(38.5-181.3) %hours in the 78 infants in the control group (fig
3⇓). In the experimental group this was a reduction of 58%
(95% confidence interval 35% to 73%, P<0.001). The difference
was primarily caused by a reduction in hypoxia (P=0.0012).
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None of the other secondary or exploratory outcomes differed
statistically significantly between the groups (table 2⇓). There
was a trend towards better survival in the experimental group
(table 3⇓).
Of the recorded physiological variables and interventions during
the intervention period in the first 72 hours of life, only the use
of echocardiography and the occurrence and treatment of patent
ductus arteriosus differed substantially (table 4⇓).
The eight centres contributed 6, 8, 9, 11, 21, 36, 36, and 39
participants. The intervention effect showed significant
heterogeneity among the centres (P<0.001). Removal of one
centre with 36 infants resulted in the heterogeneity being
insignificant (P=0.62). This centre had the largest reduction in
burden in the intervention group. A post hoc sensitivity analysis
reducing the mean effect of the intervention in this centre to a
value equal to the mean effect in the rest of the centres resulted
in a significant reduction in burden of 31% (P=0.0497).
No severe adverse reactions were associated with the device,
but 16 infants had skin marks from the NIRS sensors: four in
the intervention group and 12 in the control group (P=0.03).
The INVOS 5100C and NIRO 200NXwere used in six and two
centres, respectively.
Discussion
Cerebral oxygenation can be stabilised in extremely preterm
infants during the first three days of life by using cerebral near
infrared spectroscopy (NIRS) oximetry monitoring combined
with a dedicated treatment guideline. The trial was not powered
to detect differences in clinical outcomes, but we found an
unexpected, borderline significant reduction of all cause
mortality at term equivalent age in the NIRS group. We
encountered no severe adverse reactions, but 10% of the infants
developed skin marks possibly from pressure or heat from the
NIRS sensors.
Strengths and limitations of this study
The strengths of the trial include early and continuous
monitoring during the important transitional phase, utilisation
of a specific and evidence based treatment guideline,18 dedicated
software that supports the implementation of the treatment
guideline, and a “burden alarm” that warns when hypoxia or
hyperoxia is accumulating. Multiple centres and the use of
several NIRS devices ensure greater generalisability if the
findings. The limitations of cerebral NIRS are poor repeatability
of measurements and differences between the varied devices,
which we systematically dealt with by pretrial testing and
comparisons between the devices.24 25
This study has several limitations. Firstly, repositioning of the
NIRS sensor can change the regional tissue haemoglobin oxygen
saturation (rStO2).
12 30Out of range rStO2 values will on average
tend to normalise after the sensor has been repositioned
(regression towards themean). This means that any repositioning
motivated by out of range rStO2 values will introduce a bias on
the primary outcome reducing out of range rStO2 only in the
group with visible NIRS. Secondly, the combination of NIRS
monitoring and a treatment guideline is a complex intervention
and many factors influence how this interacts with the standard
care of infants. The treatment guideline is a list of possible
interventions and leaves the choice to the discretion of the
attending clinical staff. One centre used cerebral NIRS as part
of standard monitoring before the start of the trial; the remaining
centres had no experience with rStO2 guided treatment. A
learning curve would thus be expected. Thirdly, blinding of
group allocation to clinical staff was not possible. This could
lead to selective collateral intervention in one of the treatment
groups leading to biased intervention effects.31-34 We reduced
the impact of this problem by centralised outcome assessments
blinded to intervention group.
The intervention effect differed significantly among the centres.
The centre causing this heterogeneity had four dedicated
neonatologists doing all trial related clinical management,
working in shifts during the intervention period of 72 hours,
whereas the other centres had regular clinical staff attending
the study participants. It is thus not surprising that this centre
had the largest treatment effect. On the other hand it is also
possible that bias was increased by close attention to the cerebral
oximetry signal and repositioning of the sensor. We therefore
did the sensitivity analysis, which demonstrated a reduced, but
still significant effect. In future larger trials it will be important
to ensure a more homogenous intervention by education of staff.
Clinical outcomes
The clinical outcomes did not differ significantly. In the
experimental NIRS group we saw trends towards a reduction
in severe brain injury and, surprisingly, all cause mortality. We
assume that a reduction in burden of hypoxia and hyperoxia can
reduce the risk of brain injury and impaired neurodevelopmental
but not necessarily impact on survival. However, cerebral
oxygenation may serve as an indicator of the sufficiency of
systemic circulation and as such help to ensure sufficient
oxygenation of other vital organs during the first critical days.
The list of causes of death did not suggest any particular causal
pathway. Another simple explanation for the potential benefit
of being in the experimental group could be the extra attention
paid to the infants by the clinical staff motivated by the alarms.
In contrast, the trends towards increased risk of
bronchopulmonary dysplasia and retinopathy of prematurity
could represent unwanted effects of increased oxygenation.35
There was, however, no major differences in fractional inspired
oxygen, peripheral capillary oxygen saturation, or mean airway
pressure (table 4). The record of interventions suggested a
difference in approach only for echocardiography and detection
and treatment of patent ductus arteriosus. The benefits of treating
patent ductus arteriosus, however, remain contentious.36 Lastly,
skin marks were more common in the control group. This may
suggest poorer peripheral perfusion or may be simply due to
less careful handling of the sensor in the blinded group.
Trials of cerebral oximetry in other patient
groups
We have not been able to identify similar trials in this
population. Two randomised clinical trials in adults during
cardiac surgery compared visible cerebral NIRS monitoring
with blinded NIRS monitoring.37 38 Murkin and colleagues
reduced prolonged cerebral desaturations and found a shorter
stay in the intensive care unit and less combined mortality and
morbidity in the experimental group.37 Slater and colleagues
found no difference in cerebral rStO2 between the two groups
possibly due to poor implementation of the intervention.38 Both
these trials had a predefined decrease from baseline rStO2 as a
threshold for intervention, which is an approach to reduce the
effect of the imprecision of NIRS oximetry. This is, however,
not possible in neonatology as most ill infants are compromised
from birth, thus the baseline rStO2 cannot be assumed to be safe.
Furthermore, the sensor has to be repositioned repeatedly for
long time monitoring. We have to rely on the absolute value of
rStO2 and on absolute thresholds for intervention.
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Trials in preterm infants with clinically
relevant outcomes are needed
The present results do not yet support the routine application
of cerebral NIRS in extremely preterm infants. Although there
were trends towards benefit and no record of serious adverse
reactions, cerebral NIRS is demanding and may have unwanted
effects. NIRS requires manipulation of vulnerable extremely
preterm infants, requires additional staff time, and is costly in
economical terms. As such, definitive evidence of benefit for
improvement of clinically relevant outcomes is needed.We plan
on doing a neurodevelopmental outcome assessment at two
years corrected age; this phase II trial did not have the power
to detect a difference. Therefore, further randomised clinical
trials are needed. Such trials require a substantially greater
number of infants to assess clinically relevant outcomes and
thus require the involvement of many more centres. Several
factors must be dealt with in the planning of such phase III trials.
The appropriateness of the rStO2 thresholds for intervention
should be reconsidered and new appraisals of the available NIRS
oximeters should be made to take advantage of technical
improvements. The treatment guideline should be reviewed. A
training and certification programme for clinical staff should
be provided before the start of such a trial.
Conclusion
In summary, the burden of cerebral hypoxia and hyperoxia was
significantly reduced in extremely preterm infants monitored
by NIRS and treated according to a dedicated treatment
guideline. To assess the long term benefit and harm of the
combination of NIRS and an updated treatment guideline, larger
randomised clinical trials are needed.
We thank the families, nurses, doctors, and research assistants who
took part in the trial; Jørn Wetterslev (Copenhagen Trial Unit) for help
with the sample size estimation taking twins into consideration; and
Heike Rabe (Southampton), Jan Miletin (Dublin), and Armin Kock
(Tübingen) for their contribution as the data safety monitoring committee.
The European Clinical Research Infrastructures Network (Ecrin.org)
reviewed the protocol and supported the trial.
Local investigators: Paloma López-Ortego, María Carmen Bravo, Marta
Ybarra, Fernando Cabañas, Berndt Urlesberger, Corinna Binder,
Mmoloki Kenosi, Gavin Hawkes, Ida Sirgiovanni, Ita Herlihy, Andrea
Edwards, and Cristine Sortica da Costa. Janus Engstrøm, data manager
and electronic case record form developer, The Copenhagen Trial Unit,
Centre for Clinical Intervention Research.
Contributors: SH-S, AP, TA, TAU, FvB, MB, OC, ED, MF, CG, BG, CH,
PL, AMP, PW, GP, WvO, GP, MW and GG conceived and designed
the study. SH-S, MB, CG, BG, CH, WvO, AMP, and GG designed the
data collection instruments. JR designed the boxes for blinding the
device displays and designed and maintained the NIRS data collection
software. SH-S, AP, TA, TA, FvB, MB, OC, ED, ARF, MF, CH, PL, GP,
AMP, LS, and GG assisted with acquisition of the data. SH-S, MB, CG,
CH, WvO, AMP, PW, and GG analysed the data. SH-S, CG, and GG
wrote the initial draft. SH-S, CG, BG, AMP, and GG provided
administrative, technical, and material support and supervised the study.
All authors critically reviewed revised versions of the paper and approved
the final draft for submission. All the authors had access to the data and
contributed substantially to the submitted report. SH-S and GG are the
guarantors.
Funding: This work was supported by an unconditional and unrestricted
grant from the Danish Council for Strategic Research (DKK 11,100,105).
The funder had no role in the design, conduct, or analysis of the trial.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no
support from any organisation for the submitted work; no financial
relationships with any organisations that might have an interest in the
submitted work in the previous three years; no other relationships or
activities that could appear to have influenced the submitted work.
Ethical approval: This study was approved by the local ethics
committees: clinical research ethics committee of the Cork Teaching
Hospitals (EMC 3 (xxx) 03/07/12); NRES Committee East of
England—Cambridge South (12/EE/0329); Ethikkommission
Medizinische Universität Graz (24-261 ex (11/12)); De Videnskabetiske
Komiteer—Region Hovedstaden (H-4-2012-028); CPPSud-Est III—Lyon
(HCL/P 2012.728); Direzione Scientifica-Comitato di Etica—The IRCCS
Fondazione Ca’ Granda Ospedale Maggiore Policlinico (549/12-all.3);
Medisch Ethische Toetsingscommissie—Universitair Medisch Centrum
Utrecht (WAG/rc/12/ 036774); and Comité Ético de Investigación Clínica
del Hospital Universitario “La Paz” de Madrid (15/2011). All participants
gave informed consent before taking part in the trial.
Data sharing: Patient level data are available at from the corresponding
author at request. Consent was not obtained but the presented data
are anonymised and risk of identification is low.
Transparency: SH-S affirms that the manuscript is an honest, accurate,
and transparent account of the study being reported; that no important
aspects of the study have been omitted; and that any discrepancies
from the study as planned (and, if relevant, registered) have been
explained.
1 Hansen B, Hoff B, Greisen G, Mortensen EL for the Danish ETFOL study group. Early
nasal continuous positive airway pressure in a cohort of the smallest infants in Denmark:
neurodevelopmental outcome at five years of age. Acta Paediatrica 2004;93:190-5.
2 Serenius F, Sjörs G, Blennow M, Fellman V, Holmstrom G, Marsal K, et al. EXPRESS
study shows significant regional differences in 1-year outcome of extremely preterm infants
in Sweden. Acta Paediatr 2013;103:27-37.
3 Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal
outcomes of extremely preterm infants from the NICHD Neonatal Research Network.
Pediatrics 2010;126:443-56.
4 Noori S, Stavroudis TA, Seri I. Systemic and cerebral hemodynamics during the transitional
period after premature birth. Clin Perinatol 2009;36:723-36-v.
5 Hunt RW, Evans N, Rieger I, Kluckow M. Low superior vena cava flow and
neurodevelopment at 3 years in very preterm infants. J Pediatr 2004;145:588-92.
6 Kluckow M, Evans N. Superior vena cava flow in newborn infants: a novel marker of
systemic blood flow. Arch Dis Child Fetal Neonatal Ed 2000;82:F182-7.
7 Wolf M, Greisen G. Advances in near-infrared spectroscopy to study the brain of the
preterm and term neonate. Clin Perinatol 2009;36:807-34, vi.
8 Greisen G, Leung T, Wolf M. Has the time come to use near-infrared spectroscopy as a
routine clinical tool in preterm infants undergoing intensive care? Phil Trans R Soc A
2011;369:4440-51.
9 Wintermark P, Hansen A, Warfield SK, Dukhovny D, Soul JS. Near-infrared spectroscopy
versus magnetic resonance imaging to study brain perfusion in newborns with
hypoxic-ischemic encephalopathy treated with hypothermia. Neuroimage 2014;85(Pt
1)287-93.
10 Taussky P, O’Neal B, Daugherty WP, Luke S, Thorpe D, Pooley RA, et al. Validation of
frontal near-infrared spectroscopy as noninvasive bedside monitoring for regional cerebral
blood flow in brain-injured patients. Neurosurg Focus 2012;32:E2.
11 Alderliesten T, Lemmers PMA, van Haastert IC, de Vries LS, Bonestroo HJC, Baerts W,
et al. Hypotension in preterm neonates: low blood pressure alone does not affect
neurodevelopmental outcome. J Pediatr 2014;164:986-91.
12 Sorensen LC, Greisen G. Precision of measurement of cerebral tissue oxygenation index
using near-infrared spectroscopy in preterm neonates. J Biomed Opt 2006;11:054005.
13 Noori S, McCoy M, Anderson MP, et al. Changes in cardiac function and cerebral blood
flow in relation to peri/intraventricular hemorrhage in extremely preterm infants. J Pediatr
2014;164:264-70.e1-3.
14 Kurth CD, Levy WJ, McCann J. Near-infrared spectroscopy cerebral oxygen saturation
thresholds for hypoxia-ischemia in piglets. J Cereb Blood Flow Metab 2002;22:335-41.
15 Kurth CD, Mccann JC, Wu J, Miles L, Loepke AW. Cerebral oxygen saturation-time
threshold for hypoxic-ischemic injury in piglets. Anesth Analg 2009;108:1268-77.
16 Gerstner B, DeSilva TM, Genz K, Armstrong A, Brehmer F, Neve RL, et al. Hyperoxia
causes maturation-dependent cell death in the developing white matter. J Neurosci
2008;28:1236-45.
17 Yis U, Kurul SH, Kumral A, Cilaker S, Tugyan K, Genc S, et al. Hyperoxic exposure leads
to cell death in the developing brain. Brain Dev 2008;30:556-62.
18 Pellicer A, Greisen G, Benders M, Claris O, Dempsey EM, Fumagalli M, et al. The
SafeBoosC phase ii randomised clinical trial: a treatment guideline for targeted
near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely
preterm infants. Neonatology 2013;104:171-8.
19 Hyttel-Sørensen S, Austin T, van Bel F, Benders M, Claris O, Dempsey EM, et al. Clinical
use of cerebral oximetry in extremely preterm infants is feasible. Dan Med J
2013;60:A4533.
20 Hyttel-Sørensen S, Austin T, van Bel F, Benders M, Claris O, Dempsey EM, et al. A phase
II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline
versus treatment as usual for extremely preterm infants during the first three days of life
(SafeBoosC): study protocol for a randomized controlled trial. Trials 2013;14:120.
21 E6 (R1) Guideline for Good Clinical Practice. International Conference on Harmonisation
2009;1-48. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/
09/WC500002874.pdf.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:g7635 doi: 10.1136/bmj.g7635 (Published 5 January 2015) Page 5 of 11
RESEARCH
What is already known on this topic
Extremely preterm infants are at risk of neurodevelopmental impairment
Cerebral near infrared spectometry (NIRS) oximetry enables continuous estimation of the oxygen balance of the brain tissue and has
been shown to correlate with clinical outcome
The possibility of cerebral oxygen imbalance being reduced by a dedicated treatment guideline in extremely preterm infants has not yet
been tested in a randomised trial
What this study adds
The combination of cerebral NIRS oximetry and a dedicated treatment guideline reduced the amount of oxygen imbalance in the brain
of extremely preterm infants during the first three days of life
No severe adverse reactions were associated with the device
Larger trials powered for relevant clinical outcomes are needed to test the clinical relevance of the present findings
22 Dix LM, van Bel F, BaertsW, Lemmers PM. Comparing near-infrared spectroscopy devices
and their sensors for monitoring regional cerebral oxygen saturation in the neonate. Pediatr
Res 2013;74:557-63.
23 Dullenkopf A, Frey B, Baenziger O, Gerber A, Weiss M. Measurement of cerebral
oxygenation state in anaesthetized children using the INVOS 5100 cerebral oximeter.
Pediatr Anesth 2003;13:384-91.
24 Hyttel-Sørensen S, Kleiser S, Wolf M, Greisen G. Calibration of a prototype NIRS oximeter
against two commercial devices on a blood-lipid phantom. Biomed Opt Express
2013;4:1662.
25 Hyttel-Sørensen S, Sorensen LC, Riera J, Greisen G. Tissue oximetry: a comparison of
mean values of regional tissue saturation, reproducibility and dynamic range of four
NIRS-instruments on the human forearm. Biomed Opt Express 2011;2:3047-57.
26 Hyttel-Sørensen S, Hessel TW, Greisen G. Peripheral tissue oximetry: comparing three
commercial near-infrared spectroscopy oximeters on the forearm. J Clin Monit Comput
2014;28:149-55
27 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria.
Pediatr Clin North Am 1986;33:179-201.
28 International Committee for the Classification of Retinopathy of Prematurity. The
International Classification of Retinopathy of Prematurity revisited. 2005; 991-9.
29 Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics
1992;48:577-85.
30 Hessel TW, Hyttel-Sørensen S, Greisen G. Cerebral oxygenation after birth—a comparison
of INVOS ®and FORE-SIGHT™ near-infrared spectroscopy oximeters. Acta Paediatr
2014;103:488-93.
31 Savović J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported
study design characteristics on intervention effect estimates from randomized, controlled
trials. Ann Intern Med 2012;157:429-38.
32 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies
between large and small randomized trials in meta-analyses. Ann Intern Med
2001;135:982-9.
33 Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of
bias in treatment effect estimates in controlled trials with different interventions and
outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
34 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions
of methodological quality associated with estimates of treatment effects in controlled trials.
JAMA 1995;273:408-12.
35 SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research
Network, Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm
infants. N Engl J Med 2010;362:1970-9.
36 Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to
accept the null hypothesis? J Perinatol 2010;30:241-52.
37 Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, et al. Monitoring
brain oxygen saturation during coronary bypass surgery: a randomized, prospective study.
Anesth Analg 2007;104:51-8.
38 Slater JP, Guarino T, Stack J, Vinod K, Bustami RT, Brown JM, et al.Cerebral oxygen
desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. Ann
Thorac Surg 2009;87:36-44; discussion 44-5.
Accepted: 21 November 2014
Cite this as: BMJ 2015;350:g7635
This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works
on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:g7635 doi: 10.1136/bmj.g7635 (Published 5 January 2015) Page 6 of 11
RESEARCH
Tables
Table 1| Baseline characteristics of infants. Values are numbers (percentages) unless stated otherwise
Blinded NIRS (control) (n=80)NIRS (n=86)Characteristics
880 (490-1330)806 (410-1286)Median (range) birth weight (g)
26.8 (25.5-27.6))26.6 (25.7-27.4)Median (interquartile range) gestational age at birth (weeks)
25 (31)28 (33)Gestational age <26 weeks
34 (43)44 (51)Male sex
14 (18)20 (23)Twins
56 (71)58 (67)Prenatal steroids (complete course)
32 (40)26 (31)Prolonged rupture of membranes
7 (9)6 (7)Maternal clinical chorioamnionitis
14 (18)15 (18)Apgar score ≤5 at 5 minutes
7.31 (0.096)7.33 (0.088)Mean (SD) umbilical arterial pH
NIRS=near infrared spectroscopy oximetry.
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Table 2| Outcome measures. Values are number affected/number in group (percentage) unless stated otherwise
Adjusted P value
(unadjusted)
Adjusted relative risk
(95% CI)
Relative change in %
(95% CI)
Blinded NIRS (control)
(n=80)NIRS (n=86)Outcomes
Primary
<0.001*NA−58 (−35 to −74)81.3 (38.5-181.3) (n=78)36.1 (9.2-79.5)Median (interquartile range) burden
of hypoxia and hyperoxia (%hours)
Secondary
0.10 (0.049)0.50 (0.29 to 1.00)NA20/80 (25)12/86 (14)All cause mortality at term
Brain injury on cerebral
ultrasonography:
0.11 (0.053)—NA26/77 (34)21/80 (26)None
—NA33/77 (43)49/80 (61)Mild-moderate
—NA18/77 (23)10/80 (13)Severe
Exploratory
0.0012*NA−58 (−24 to −76)53.6 (17.4-171.3) (n=78)16.6 (5.4-68.1)Median (interquartile range) burden
of hypoxia (%hours)
0.98*NA1 (−35 to 194)1.1 (0.1-23.4) (n=78)1.2 (0.3-9.6)Mean (SD) burden of hyperoxia
(%hours)
0.690.83 (0.33 to 1.94)NA10/80 (13)9/86 (11)Necrotising enterocolitis†
0.201.27 (0.94 to 1.50)NA28/60 (47)41/72 (57)Bronchopulmonary dysplasia‡
0.201.64 (0.75 to 3.00)NA8/80 (10)14/86 (16)Retinopathy of prematurity§
NA=not applicable.
*Data were log transformed to normalise distributions. P values originate from analysis with adjustment for gestational age category and trial site indicator and are
adjusted for multiplicity. Medians and interquartile ranges are based on raw data obtained before transformation.
†Modified Bell’s stage 2 or 3.
‡Extra oxygen requirement at 36 weeks of gestation.
§Stage ≥3 on international classification.
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Table 3| Causes of death
OtherInfection/sepsis
Necrotising
enterocolitisCirculatory failureRDS/respiratory failureGMH-IVH/PVLGroup
031341NIRS
423362Blinded NIRS (control)
GMH-IVH/PVL=germinal matrix-intraventricular haemorrhage /periventricular leukomalacia; RDS=respiratory distress syndrome; NIRS=near infrared spectroscopy
oximetry.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:g7635 doi: 10.1136/bmj.g7635 (Published 5 January 2015) Page 9 of 11
RESEARCH
Table 4| Death, interventions, and physiological variables during intervention period of first 72 hours of life. Values are numbers (percentages)
unless stated otherwise
Blinded NIRS (control) (n=80)NIRS (n=86)Variables
6 (7.5)3 (3.5)Deaths
Respiratory:
63 (78.8)64 (74.4)Surfactant administered
54 (67.5)57 (66.3)Mechanical ventilation
3.4 (8.7)3.5 (9.8)Mean (SD) postnatal age at onset (hours)
53.0 (25.2)52.2 (24.9)Mean (SD) duration (hours)
Circulatory:
38 (47.5)53 (61.6)Echocardiography performed
9 (11.3)19 (22.1)Haemodynamic significant patent ductus arteriosus
5 (6.3)16 (18.6)Patent ductus arteriosus treated
19 (23.8)20 (23.3)Use of vasopressors/inotropes
0.9 (1.9)0.6 (1.2)Mean (SD) fluid boluses
27 (33.8)24 (27.9)Any red blood cell transfusion
6 (7.5)2 (2.3)Corticosteroids
11.5 (8.9)11.1 (8.0)Mean (SD) No of blood samples
Physiological variables*:
25.4 (3.8)26.6 (4.2)Mean (SD) fractional inspired oxygen (%)
93.6 (9.1)93.6 (12.5)Mean (SD) peripheral capillary oxygen saturation (%)
7.5 (3.3)7.9 (4.1)Mean (SD) mean airway pressure (cm H2O)
152.8 (14.3)155.4 (14.6)Mean (SD) heart rate (beats/min)
35.6 (7.1)35.9 (8.4)Mean (SD) mean arterial blood pressure (mm Hg)
NIRS=near infrared spectroscopy oximetry.
*Recorded six hourly. Data were entered at1348 time points. Missing data were due to technical issues or death of child before 72 hours of life.
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Figures
Fig 1 Schematic illustration of concept of burden of hypoxia and hyperoxia and the alarm. rStO2=regional tissue haemoglobin
oxygen saturation
Fig 2 Flow of participants through study. NIRS=cerebral near infrared spectroscopy oximetry
Fig 3 Burden of hypoxia and hyperoxia by treatment group. NIRS=cerebral near infrared spectroscopy oximetry
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